Intech Biopharm (益得) recently held an institutional investor briefing where the new General Manager, Chawla Manish, detailed the company’s five-year strategic roadmap. Chawla announced that Acter is expanding its nasal spray and inhalation portfolio from Asia and China into North America. The company is set to sign a sales agreement with an international pharmaceutical giant to bring a developmental drug to the US market, targeting a US$1.5 billion (approx. NT$47 billion) annual opportunity.

Strategic Insights:

• Leadership: Chawla Manish, formerly of Lotus Pharmaceutical, brings extensive experience in developing and launching generics and 505(b)(2) products, having submitted over 100 filings in US and European markets.
• Product Focus: Acter specializes in Metered Dose Inhalers (MDI), Nasal Sprays, and Dry Powder Inhalers (DPI) for respiratory diseases like asthma and COPD. Current products (Duasma, Synvent, Synbufo) are already marketed in Southeast Asia and Latin America.
• Market Outlook: The global asthma and COPD medication market is projected to grow from US$40.3 billion in 2024 to US$86.36 billion by 2034, with a CAGR of 7.92%. Acter is currently advancing seven MDI products and four nasal spray generics to capture this growth.

Resource: 益得生技將與國際藥廠簽署銷售合約 搶攻全美年470億元市場商機